A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.

NCT Number	NCT06679140
Lead Sponsor	Pfizer
Conditions	COVID-19 SARS-CoV-2 Infection
Enrollment	2,330 participants
Start Date	2024-12-08
Primary Completion	2027-10-03 (estimated)
Study Completion	2028-03-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-14